1. Phylogeny  
Tyrosine‐protein kinase Mer (MERTK) is a member of the TAM family of receptor tyrosine kinases, which also comprises Tyro3 and Axl. MERTK orthologs have been characterized in multiple vertebrate species, including human and rodent, indicating that it is highly conserved across these taxa (strick2010focusonmolecules pages 1-2, seitz2007macrophagesanddendritic pages 28-33, ma2011polymorphismsinthe pages 1-2). Phylogenetic analyses place MERTK in a distinct subfamily within the kinome that evolved from a common ancestral gene with its TAM counterparts, thereby sharing a conserved overall domain organization and a similar role in the regulation of phagocytosis and immune homeostasis.

2. Reaction Catalyzed  
MERTK catalyzes the transfer of the γ‐phosphate from ATP to specific tyrosine residues in substrate proteins. In this phosphotransfer reaction, ATP and the substrate protein combine to yield ADP and a phosphorylated substrate protein, which is essential for propagating intracellular signaling cascades (zhang2013discoveryofmer pages 1-2, huang2009structuralinsightsinto pages 1-2).

3. Cofactor Requirements  
The catalytic activity of MERTK depends on the binding of ATP and requires divalent metal ions as cofactors, with Mg²⁺ being the predominant ion that facilitates efficient catalytic turnover. The presence of Mg²⁺ is necessary for proper coordination and stabilization of ATP within the kinase’s active site (zhang2013discoveryofmer pages 1-2).

4. Substrate Specificity  
Investigations employing positional scanning peptide libraries have been used to examine the substrate specificity of MERTK. These studies indicate that MERTK phosphorylates tyrosine residues located within substrate proteins that are involved in cellular processes such as migration, survival, and efferocytosis. Although no definitive consensus motif has been uniformly established, the intrinsic substrate specificity is shaped by the particular amino acid context surrounding the target tyrosine residue (huang2009structuralinsightsinto pages 2-3).

5. Structure  
MERTK is organized as a single‐pass transmembrane receptor with a modular domain architecture. It contains an N‐terminal signal peptide that directs the protein to the secretory pathway, followed by an extracellular region composed of two immunoglobulin-like (Ig-like) C2 domains and two fibronectin type III (FN-III) domains that mediate ligand binding. A short transmembrane helix anchors the receptor to the plasma membrane, and a large cytoplasmic region houses the tyrosine kinase domain. This intracellular kinase domain contains the conserved catalytic core with an activation loop harboring key autophosphorylation sites (notably Tyr749, Tyr753, and Tyr754) and the invariant KWAIAES motif that is characteristic of TAM kinases (audo2018mertkmutationupdate pages 1-6, huang2009structuralinsightsinto pages 4-5). In addition, structural studies have detailed conformational changes upon inhibitor binding, such as a rotation of the N‐lobe relative to the C‐lobe, and have shown that the receptor can adopt both active and autoinhibited states. Proteolytic cleavage events mediated by metalloproteinases also generate soluble forms of MERTK, which are structurally analogous to the extracellular domain and serve regulatory purposes by sequestering ligands (law2015cleavageofmer pages 11-11).

6. Regulation  
MERTK regulation is initiated by ligand binding to its extracellular domains; known ligands include GAS6, Protein S, LGALS3, TUB, and TULP1. Ligand engagement promotes receptor dimerization and subsequent autophosphorylation on key tyrosine residues within the intracellular kinase domain, resulting in the formation of docking sites for downstream signaling adaptors such as GRB2 and PLCG2. These post-translational modifications are critical for full kinase activation and the propagation of signaling cascades including those mediated by MAPK1, MAPK2, FAK/PTK2, and RAC1 (audo2018mertkmutationupdate pages 1-6). Moreover, MERTK activity is further regulated by proteolytic cleavage mediated by ADAM17, which releases a soluble extracellular fragment that acts as a decoy receptor to limit ligand availability and modulate signal intensity (law2015cleavageofmer pages 11-12). In addition, the receptor’s interaction with co-receptors such as αvβ5 integrin facilitates cytoskeletal rearrangements necessary for efficient phagocytosis of apoptotic cells.

7. Function  
MERTK plays multiple roles in physiological processes by transducing signals from the extracellular environment into the cell. It is expressed in macrophages, monocytes, epithelial cells—including retinal pigment epithelium—and other cell types where it regulates diverse biological functions. In macrophages and other phagocytic cells, MERTK is essential for efferocytosis, the clearance of apoptotic cells, thereby contributing to immune homeostasis and the resolution of inflammation. In the retinal pigment epithelium, MERTK-mediated phagocytosis of rod outer segment fragments is critical for retinal maintenance and vision. Beyond its role in phagocytosis, MERTK influences cell survival, migration, differentiation, and cytoskeletal reorganization through downstream signaling pathways such as those mediated by MAP kinases, FAK, and RAC1. Dysregulation of MERTK signaling is associated with various pathologies; loss-of-function mutations in MERTK are causatively linked to inherited retinal dystrophies (for example, retinitis pigmentosa), while overexpression and aberrant activation have been implicated in tumor progression, metastasis, and therapy resistance in a range of cancers (audo2018mertkmutationupdate pages 1-6, audo2018mertkmutationupdate pages 6-10, seitz2007macrophagesanddendritic pages 28-33, nguyen2014overexpressionofmertk pages 1-2).

8. Other Comments  
Several small molecule inhibitors targeting MERTK have been developed based on structure‐based drug design. Inhibitors that bind to the ATP pocket, including substituted pyrimidine derivatives, have demonstrated high potency and selectivity, and some agents have advanced into preclinical evaluations. In addition to kinase inhibitors, targeted protein degraders have been engineered to induce ubiquitin–proteasome-mediated degradation of MERTK, reflecting alternative therapeutic strategies (cook2013mertkinhibitionin pages 12-12, zhang2013discoveryofmer pages 1-2, gadiyar2023targeteddegradationof pages 1-3). Disease associations for MERTK are diverse; mutations that result in loss of MERTK function are known to cause severe autosomal recessive inherited retinal dystrophies, while hyperactivation or overexpression is linked to cancer progression, metastasis, resistance to therapy, autoimmune disorders, and thrombotic events. Its role in inhibiting Toll-like receptor (TLR)–mediated innate immune responses further underscores its importance in maintaining immune tolerance and preventing excessive inflammation (audo2018mertkmutationupdate pages 17-19, mcdaniel2018mertkmediatesintrinsic pages 9-13).

9. References  
1. Audo, I., Mohand-Said, S., Boulanger-Scemama, E., Zanlonghi, X., Condroyer, C., Démontant, V., Boyard, F., Antonio, A., Méjécase, C., El Shamieh, S., Sahel, J.-A., & Zeitz, C. “Mertk mutation update in inherited retinal diseases.” Human Mutation, 39:887-913, Jul 2018. (audo2018mertkmutationupdate pages 1-6, audo2018mertkmutationupdate pages 6-10, audo2018mertkmutationupdate pages 17-19)  
2. Cook, R. S., Jacobsen, K. M., Wofford, A. L., DeRyckere, D., Stanford, J., Prieto, A. L., Redente, E., Sandahl, M., Hunter, D. M., Strunk, K. E., Graham, D. K., & Earp, H. S. “Mertk inhibition in tumor leukocytes decreases tumor growth and metastasis.” The Journal of Clinical Investigation, 123(8):3231-42, Aug 2013. (cook2013mertkinhibitionin pages 12-12)  
3. Evans, A. L., Blackburn, J. W. D., Taruc, K., Kipp, A., Dirk, B. S., Hunt, N. R., Barr, S. D., Dikeakos, J. D., & Heit, B. “Antagonistic coevolution of mer tyrosine kinase expression and function.” Molecular Biology and Evolution, 34:1613–1628, Jul 2017. (evans2017antagonisticcoevolutionof pages 14-15, evans2017antagonisticcoevolutionof pages 7-8)  
4. Gadiyar, V., Patel, G., Chen, J., Vigil, D., Ji, N., Campbell, V., Sharma, K., Shi, Y., Weiss, M. M., Birge, R. B., & Davra, V. “Targeted degradation of mertk and other tam receptor paralogs by heterobifunctional targeted protein degraders.” Frontiers in Immunology, Jul 2023. (gadiyar2023targeteddegradationof pages 1-3, gadiyar2023targeteddegradationof pages 13-14)  
5. Huang, X., Finerty, P., Walker, J. R., Butler-Cole, C., Vedadi, M., Schapira, M., Parker, S. A., Turk, B. E., Thompson, D. A., & Dhe-Paganon, S. “Structural insights into the inhibited states of the mer receptor tyrosine kinase.” Journal of Structural Biology, 165:88-96, Feb 2009. (huang2009structuralinsightsinto pages 1-2, huang2009structuralinsightsinto pages 4-5, huang2009structuralinsightsinto pages 5-7, huang2009structuralinsightsinto pages 7-8, huang2009structuralinsightsinto pages 9-9)  
6. Law, A.-L., Parinot, C., Chatagnon, J., Gravez, B., Sahel, J.-A., Bhattacharya, S. S., & Nandrot, E. F. “Cleavage of mer tyrosine kinase (mertk) from the cell surface contributes to the regulation of retinal phagocytosis.” Journal of Biological Chemistry, 290:4941-4952, Feb 2015. (law2015cleavageofmer pages 11-11, law2015cleavageofmer pages 11-12)  
7. McDaniel, N. K., Cummings, C. T., Iida, M., Hülsé, J., Pearson, H. E., Vasileiadi, E., Parker, R. E., Orbuch, R. A., Ondracek, O. J., Welke, N. B., Kang, G. H., Davies, K. D., Wang, X., Frye, S. V., Earp, H. S., Harari, P. M., Kimple, R. J., DeRyckere, D., Graham, D. K., & Wheeler, D. L. “Mertk mediates intrinsic and adaptive resistance to axl-targeting agents.” Molecular Cancer Therapeutics, 17:2297-2308, Nov 2018. (mcdaniel2018mertkmediatesintrinsic pages 1-5, mcdaniel2018mertkmediatesintrinsic pages 25-33, mcdaniel2018mertkmediatesintrinsic pages 9-13)  
8. Nguyen, K., Tsou, W., Calarese, D., Kimani, S., Singh, S., Hsieh, S., Liu, Y., Lu, B., Wu, Y., Garforth, S., Almo, S., & Kotenko, S. “Overexpression of mertk receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity.” The Journal of Biological Chemistry, 289:25737-25749, Jul 2014. (nguyen2014overexpressionofmertk pages 1-2, nguyen2014overexpressionofmertk pages 2-3, nguyen2014overexpressionofmertk pages 3-4, nguyen2014overexpressionofmertk pages 7-8, nguyen2014overexpressionofmertk pages 8-9, nguyen2014overexpressionofmertk pages 9-10, nguyen2014overexpressionofmertk pages 10-11, nguyen2014overexpressionofmertk pages 12-13)  
9. Seitz, H. M., Camenisch, T. D., Lemke, G., Earp, H. S., & Matsushima, G. K. “Macrophages and dendritic cells use different axl/mertk/tyro3 receptors in clearance of apoptotic cells.” The Journal of Immunology, 178:5635-5642, May 2007. (seitz2007macrophagesanddendritic pages 28-33, seitz2007macrophagesanddendritic pages 113-117, seitz2007macrophagesanddendritic pages 117-119, seitz2007macrophagesanddendritic pages 24-28, seitz2007macrophagesanddendritic pages 60-68, seitz2007macrophagesanddendritic pages 68-72)  
10. Thorp, E., Vaisar, T., Subramanian, M., Mautner, L., Blobel, C., & Tabas, I. “Shedding of the mer tyrosine kinase receptor is mediated by adam17 protein through a pathway involving reactive oxygen species, protein kinase cδ, and p38 mitogen-activated protein kinase (MAPK).” Journal of Biological Chemistry, 286:33335-33344, Sep 2011. (thorp2011sheddingofthe pages 1-2)  
11. Wang, Y., Moncayo, G., Morin, P., Xue, G., Grzmil, M., Lino, M. M., Clément-Schatlo, V., Frank, S., Merlo, A., & Hemmings, B. A. “Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme.” Oncogene, 32:872-882, Apr 2013. (wang2013merreceptortyrosine pages 1-3, wang2013merreceptortyrosine pages 10-11)  
12. Cackowski, F. C., Eber, M. R., Rhee, J., Decker, A. M., Yumoto, K., Berry, J. E., Lee, E., Shiozawa, Y., Jung, Y., & Taichman, R. S. “Mer tyrosine kinase regulates disseminated prostate cancer cellular dormancy.” Journal of Cellular Biochemistry, Apr 2017. (cackowski2017mertyrosinekinase pages 1-6)  
13. Dransfield, I., Zagórska, A., Lew, E., Michail, K., & Lemke, G. “Mer receptor tyrosine kinase mediates both tethering and phagocytosis of apoptotic cells.” Cell Death & Disease, 6:e1646, Feb 2015. (dransfield2015merreceptortyrosine pages 9-10)  
14. Linger, R. M., Keating, A. K., Earp, H. S., & Graham, D. K. “Taking aim at mer and axl receptor tyrosine kinases as novel therapeutic targets in solid tumors.” Expert Opinion on Therapeutic Targets, 14:1073-1090, Sep 2010. (linger2010takingaimat pages 8-10, linger2010takingaimat pages 19-21)  
15. Myers, K. V., Amend, S. R., & Pienta, K. J. “Targeting tyro3, axl and mertk (tam receptors): implications for macrophages in the tumor microenvironment.” Molecular Cancer, May 2019. (myers2019targetingtyro3axl pages 1-2)  
16. Rothlin, C. V., Leighton, J. A., & Ghosh, S. “Tyro3, axl, and mertk receptor signaling in inflammatory bowel disease and colitis-associated cancer.” Inflammatory Bowel Diseases, 20:1472-1480, Aug 2014. (rothlin2014tyro3axland pages 1-2)  
17. Schoumacher, M., & Burbridge, M. “Key roles of axl and mer receptor tyrosine kinases in resistance to multiple anticancer therapies.” Current Oncology Reports, Mar 2017. (schoumacher2017keyrolesof pages 2-4)  
18. Waterborg, C. E. J., Beermann, S., Broeren, M. G. A., Bennink, M. B., Koenders, M. I., van Lent, P. L. E. M., van den Berg, W. B., van der Kraan, P. M., & van de Loo, F. A. J. “Protective role of the mer tyrosine kinase via efferocytosis in rheumatoid arthritis models.” Frontiers in Immunology, Apr 2018. (waterborg2018protectiveroleof pages 13-14)  
19. Wu, Y., Singh, S., Georgescu, M., & Birge, R. “A role for mer tyrosine kinase in αvβ5 integrin-mediated phagocytosis of apoptotic cells.” Journal of Cell Science, 118:539-553, Feb 2005. (wu2005arolefor pages 1-2, wu2005arolefor pages 7-9, wu2005arolefor pages 9-11, wu2005arolefor pages 14-15)  
20. Zhang, W., McIver, A. L., Stashko, M. A., DeRyckere, D., Branchford, B. R., Hunter, D., Kireev, D., Miley, M. J., Norris-Drouin, J., Stewart, W. M., Lee, M., Sather, S., Zhou, Y., Di Paola, J. A., Machius, M., Janzen, W. P., Earp, H. S., Graham, D. K., Frye, S. V., & Wang, X. “Discovery of mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis.” Journal of Medicinal Chemistry, 56:9693-9700, Dec 2013. (zhang2013discoveryofmer pages 1-2, zhang2013discoveryofmer pages 4-5)  
21. Ma, G. Z., Stankovich, J., Kilpatrick, T., Binder, M., & Field, J. “Polymorphisms in the receptor tyrosine kinase mertk gene are associated with multiple sclerosis susceptibility.” PLoS ONE, Feb 2011. (ma2011polymorphismsinthe pages 1-2)

References

1. (audo2018mertkmutationupdate pages 1-6): Isabelle Audo, Saddek Mohand-Said, Elise Boulanger-Scemama, Xavier Zanlonghi, Christel Condroyer, Vanessa Démontant, Fiona Boyard, Aline Antonio, Cécile Méjécase, Said El Shamieh, José-Alain Sahel, and Christina Zeitz. Mertk mutation update in inherited retinal diseases. Human Mutation, 39:887-913, Jul 2018. URL: https://doi.org/10.1002/humu.23431, doi:10.1002/humu.23431. This article has 71 citations and is from a domain leading peer-reviewed journal.

2. (audo2018mertkmutationupdate pages 6-10): Isabelle Audo, Saddek Mohand-Said, Elise Boulanger-Scemama, Xavier Zanlonghi, Christel Condroyer, Vanessa Démontant, Fiona Boyard, Aline Antonio, Cécile Méjécase, Said El Shamieh, José-Alain Sahel, and Christina Zeitz. Mertk mutation update in inherited retinal diseases. Human Mutation, 39:887-913, Jul 2018. URL: https://doi.org/10.1002/humu.23431, doi:10.1002/humu.23431. This article has 71 citations and is from a domain leading peer-reviewed journal.

3. (cook2013mertkinhibitionin pages 12-12): Rebecca S. Cook, Kristen M. Jacobsen, Anne M. Wofford, Deborah DeRyckere, Jamie Stanford, Anne L. Prieto, Elizabeth Redente, Melissa Sandahl, Debra M. Hunter, Karen E. Strunk, Douglas K. Graham, and H. Shelton Earp. Mertk inhibition in tumor leukocytes decreases tumor growth and metastasis. The Journal of clinical investigation, 123 8:3231-42, Aug 2013. URL: https://doi.org/10.1172/jci67655, doi:10.1172/jci67655. This article has 200 citations.

4. (evans2017antagonisticcoevolutionof pages 14-15): Amanda L. Evans, Jack W.D. Blackburn, Kyle Taruc, Angela Kipp, Brennan S. Dirk, Nina R. Hunt, Stephen D. Barr, Jimmy D. Dikeakos, and Bryan Heit. Antagonistic coevolution of mer tyrosine kinase expression and function. Molecular Biology and Evolution, 34:1613–1628, Jul 2017. URL: https://doi.org/10.1093/molbev/msx102, doi:10.1093/molbev/msx102. This article has 23 citations and is from a highest quality peer-reviewed journal.

5. (gadiyar2023targeteddegradationof pages 1-3): Varsha Gadiyar, Gopi Patel, Jesse Chen, Dominico Vigil, Nan Ji, Veronica Campbell, Kirti Sharma, Yatao Shi, Matthew M. Weiss, Raymond B. Birge, and Viralkumar Davra. Targeted degradation of mertk and other tam receptor paralogs by heterobifunctional targeted protein degraders. Frontiers in Immunology, Jul 2023. URL: https://doi.org/10.3389/fimmu.2023.1135373, doi:10.3389/fimmu.2023.1135373. This article has 10 citations and is from a peer-reviewed journal.

6. (gadiyar2023targeteddegradationof pages 13-14): Varsha Gadiyar, Gopi Patel, Jesse Chen, Dominico Vigil, Nan Ji, Veronica Campbell, Kirti Sharma, Yatao Shi, Matthew M. Weiss, Raymond B. Birge, and Viralkumar Davra. Targeted degradation of mertk and other tam receptor paralogs by heterobifunctional targeted protein degraders. Frontiers in Immunology, Jul 2023. URL: https://doi.org/10.3389/fimmu.2023.1135373, doi:10.3389/fimmu.2023.1135373. This article has 10 citations and is from a peer-reviewed journal.

7. (huang2009structuralinsightsinto pages 1-2): Xudong Huang, Patrick Finerty, John R. Walker, Christine Butler-Cole, Masoud Vedadi, Matthieu Schapira, Sirlester A. Parker, Benjamin E. Turk, Debra A. Thompson, and Sirano Dhe-Paganon. Structural insights into the inhibited states of the mer receptor tyrosine kinase. Journal of Structural Biology, 165:88-96, Feb 2009. URL: https://doi.org/10.1016/j.jsb.2008.10.003, doi:10.1016/j.jsb.2008.10.003. This article has 67 citations and is from a peer-reviewed journal.

8. (huang2009structuralinsightsinto pages 4-5): Xudong Huang, Patrick Finerty, John R. Walker, Christine Butler-Cole, Masoud Vedadi, Matthieu Schapira, Sirlester A. Parker, Benjamin E. Turk, Debra A. Thompson, and Sirano Dhe-Paganon. Structural insights into the inhibited states of the mer receptor tyrosine kinase. Journal of Structural Biology, 165:88-96, Feb 2009. URL: https://doi.org/10.1016/j.jsb.2008.10.003, doi:10.1016/j.jsb.2008.10.003. This article has 67 citations and is from a peer-reviewed journal.

9. (huang2009structuralinsightsinto pages 5-7): Xudong Huang, Patrick Finerty, John R. Walker, Christine Butler-Cole, Masoud Vedadi, Matthieu Schapira, Sirlester A. Parker, Benjamin E. Turk, Debra A. Thompson, and Sirano Dhe-Paganon. Structural insights into the inhibited states of the mer receptor tyrosine kinase. Journal of Structural Biology, 165:88-96, Feb 2009. URL: https://doi.org/10.1016/j.jsb.2008.10.003, doi:10.1016/j.jsb.2008.10.003. This article has 67 citations and is from a peer-reviewed journal.

10. (huang2009structuralinsightsinto pages 9-9): Xudong Huang, Patrick Finerty, John R. Walker, Christine Butler-Cole, Masoud Vedadi, Matthieu Schapira, Sirlester A. Parker, Benjamin E. Turk, Debra A. Thompson, and Sirano Dhe-Paganon. Structural insights into the inhibited states of the mer receptor tyrosine kinase. Journal of Structural Biology, 165:88-96, Feb 2009. URL: https://doi.org/10.1016/j.jsb.2008.10.003, doi:10.1016/j.jsb.2008.10.003. This article has 67 citations and is from a peer-reviewed journal.

11. (law2015cleavageofmer pages 11-11): Ah-Lai Law, Célia Parinot, Jonathan Chatagnon, Basile Gravez, José-Alain Sahel, Shomi S. Bhattacharya, and Emeline F. Nandrot. Cleavage of mer tyrosine kinase (mertk) from the cell surface contributes to the regulation of retinal phagocytosis. Journal of Biological Chemistry, 290:4941-4952, Feb 2015. URL: https://doi.org/10.1074/jbc.m114.628297, doi:10.1074/jbc.m114.628297. This article has 76 citations and is from a domain leading peer-reviewed journal.

12. (law2015cleavageofmer pages 11-12): Ah-Lai Law, Célia Parinot, Jonathan Chatagnon, Basile Gravez, José-Alain Sahel, Shomi S. Bhattacharya, and Emeline F. Nandrot. Cleavage of mer tyrosine kinase (mertk) from the cell surface contributes to the regulation of retinal phagocytosis. Journal of Biological Chemistry, 290:4941-4952, Feb 2015. URL: https://doi.org/10.1074/jbc.m114.628297, doi:10.1074/jbc.m114.628297. This article has 76 citations and is from a domain leading peer-reviewed journal.

13. (mcdaniel2018mertkmediatesintrinsic pages 1-5): Nellie K. McDaniel, Christopher T. Cummings, Mari Iida, Justus Hülse, Hannah E. Pearson, Eleana Vasileiadi, Rebecca E. Parker, Rachel A. Orbuch, Olivia J. Ondracek, Noah B. Welke, Grace H. Kang, Kurtis D. Davies, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp, Paul M. Harari, Randall J. Kimple, Deborah DeRyckere, Douglas K. Graham, and Deric L. Wheeler. Mertk mediates intrinsic and adaptive resistance to axl-targeting agents. Molecular Cancer Therapeutics, 17:2297-2308, Nov 2018. URL: https://doi.org/10.1158/1535-7163.mct-17-1239, doi:10.1158/1535-7163.mct-17-1239. This article has 54 citations and is from a peer-reviewed journal.

14. (nguyen2014overexpressionofmertk pages 12-13): K. Nguyen, W. Tsou, D. Calarese, S. Kimani, Sukhwinder Singh, S. Hsieh, Yongzhang Liu, Bin Lu, Yi Wu, S. Garforth, S. Almo, S. Kotenko, and R. Birge. Overexpression of mertk receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity*. The Journal of Biological Chemistry, 289:25737-25749, Jul 2014. URL: https://doi.org/10.1074/jbc.m114.570838, doi:10.1074/jbc.m114.570838. This article has 106 citations.

15. (nguyen2014overexpressionofmertk pages 2-3): K. Nguyen, W. Tsou, D. Calarese, S. Kimani, Sukhwinder Singh, S. Hsieh, Yongzhang Liu, Bin Lu, Yi Wu, S. Garforth, S. Almo, S. Kotenko, and R. Birge. Overexpression of mertk receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity*. The Journal of Biological Chemistry, 289:25737-25749, Jul 2014. URL: https://doi.org/10.1074/jbc.m114.570838, doi:10.1074/jbc.m114.570838. This article has 106 citations.

16. (nguyen2014overexpressionofmertk pages 8-9): K. Nguyen, W. Tsou, D. Calarese, S. Kimani, Sukhwinder Singh, S. Hsieh, Yongzhang Liu, Bin Lu, Yi Wu, S. Garforth, S. Almo, S. Kotenko, and R. Birge. Overexpression of mertk receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity*. The Journal of Biological Chemistry, 289:25737-25749, Jul 2014. URL: https://doi.org/10.1074/jbc.m114.570838, doi:10.1074/jbc.m114.570838. This article has 106 citations.

17. (seitz2007macrophagesanddendritic pages 28-33): Heather M Seitz, Todd D Camenisch, Greg Lemke, H Shelton Earp, and Glenn K Matsushima. Macrophages and dendritic cells use different axl/mertk/tyro3 receptors in clearance of apoptotic cells. The Journal of Immunology, 178:5635-5642, May 2007. URL: https://doi.org/10.4049/jimmunol.178.9.5635, doi:10.4049/jimmunol.178.9.5635. This article has 457 citations.

18. (strick2010focusonmolecules pages 1-2): DJ Strick. Focus on molecules: mertk. Unknown journal, 2010.

19. (thorp2011sheddingofthe pages 1-2): Edward Thorp, Tomas Vaisar, Manikandan Subramanian, Lauren Mautner, Carl Blobel, and Ira Tabas. Shedding of the mer tyrosine kinase receptor is mediated by adam17 protein through a pathway involving reactive oxygen species, protein kinase cδ, and p38 mitogen-activated protein kinase (mapk). Journal of Biological Chemistry, 286:33335-33344, Sep 2011. URL: https://doi.org/10.1074/jbc.m111.263020, doi:10.1074/jbc.m111.263020. This article has 310 citations and is from a domain leading peer-reviewed journal.

20. (wang2013merreceptortyrosine pages 10-11): Y Wang, G Moncayo, P Morin, G Xue, M Grzmil, M M Lino, V Clément-Schatlo, S Frank, A Merlo, and B A Hemmings. Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme. Oncogene, 32:872-882, Apr 2013. URL: https://doi.org/10.1038/onc.2012.104, doi:10.1038/onc.2012.104. This article has 86 citations and is from a domain leading peer-reviewed journal.

21. (audo2018mertkmutationupdate pages 17-19): Isabelle Audo, Saddek Mohand-Said, Elise Boulanger-Scemama, Xavier Zanlonghi, Christel Condroyer, Vanessa Démontant, Fiona Boyard, Aline Antonio, Cécile Méjécase, Said El Shamieh, José-Alain Sahel, and Christina Zeitz. Mertk mutation update in inherited retinal diseases. Human Mutation, 39:887-913, Jul 2018. URL: https://doi.org/10.1002/humu.23431, doi:10.1002/humu.23431. This article has 71 citations and is from a domain leading peer-reviewed journal.

22. (cackowski2017mertyrosinekinase pages 1-6): Frank C. Cackowski, Matthew R. Eber, James Rhee, Ann M. Decker, Kenji Yumoto, Janice E. Berry, Eunsohl Lee, Yusuke Shiozawa, Younghun Jung, Julio A. Aguirre‐Ghiso, and Russell S. Taichman. Mer tyrosine kinase regulates disseminated prostate cancer cellular dormancy. Journal of Cellular Biochemistry, Apr 2017. URL: https://doi.org/10.1002/jcb.25768, doi:10.1002/jcb.25768. This article has 79 citations and is from a peer-reviewed journal.

23. (dransfield2015merreceptortyrosine pages 9-10): I. Dransfield, A. Zagórska, E. Lew, K. Michail, and G. Lemke. Mer receptor tyrosine kinase mediates both tethering and phagocytosis of apoptotic cells. Cell Death &amp; Disease, 6:e1646-e1646, Feb 2015. URL: https://doi.org/10.1038/cddis.2015.18, doi:10.1038/cddis.2015.18. This article has 132 citations.

24. (evans2017antagonisticcoevolutionof pages 7-8): Amanda L. Evans, Jack W.D. Blackburn, Kyle Taruc, Angela Kipp, Brennan S. Dirk, Nina R. Hunt, Stephen D. Barr, Jimmy D. Dikeakos, and Bryan Heit. Antagonistic coevolution of mer tyrosine kinase expression and function. Molecular Biology and Evolution, 34:1613–1628, Jul 2017. URL: https://doi.org/10.1093/molbev/msx102, doi:10.1093/molbev/msx102. This article has 23 citations and is from a highest quality peer-reviewed journal.

25. (huang2009structuralinsightsinto pages 2-3): Xudong Huang, Patrick Finerty, John R. Walker, Christine Butler-Cole, Masoud Vedadi, Matthieu Schapira, Sirlester A. Parker, Benjamin E. Turk, Debra A. Thompson, and Sirano Dhe-Paganon. Structural insights into the inhibited states of the mer receptor tyrosine kinase. Journal of Structural Biology, 165:88-96, Feb 2009. URL: https://doi.org/10.1016/j.jsb.2008.10.003, doi:10.1016/j.jsb.2008.10.003. This article has 67 citations and is from a peer-reviewed journal.

26. (linger2010takingaimat pages 19-21): Rachel MA Linger, Amy K Keating, H Shelton Earp, and Douglas K Graham. Taking aim at mer and axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opinion on Therapeutic Targets, 14:1073-1090, Sep 2010. URL: https://doi.org/10.1517/14728222.2010.515980, doi:10.1517/14728222.2010.515980. This article has 200 citations and is from a peer-reviewed journal.

27. (linger2010takingaimat pages 8-10): Rachel MA Linger, Amy K Keating, H Shelton Earp, and Douglas K Graham. Taking aim at mer and axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opinion on Therapeutic Targets, 14:1073-1090, Sep 2010. URL: https://doi.org/10.1517/14728222.2010.515980, doi:10.1517/14728222.2010.515980. This article has 200 citations and is from a peer-reviewed journal.

28. (mcdaniel2018mertkmediatesintrinsic pages 25-33): Nellie K. McDaniel, Christopher T. Cummings, Mari Iida, Justus Hülse, Hannah E. Pearson, Eleana Vasileiadi, Rebecca E. Parker, Rachel A. Orbuch, Olivia J. Ondracek, Noah B. Welke, Grace H. Kang, Kurtis D. Davies, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp, Paul M. Harari, Randall J. Kimple, Deborah DeRyckere, Douglas K. Graham, and Deric L. Wheeler. Mertk mediates intrinsic and adaptive resistance to axl-targeting agents. Molecular Cancer Therapeutics, 17:2297-2308, Nov 2018. URL: https://doi.org/10.1158/1535-7163.mct-17-1239, doi:10.1158/1535-7163.mct-17-1239. This article has 54 citations and is from a peer-reviewed journal.

29. (myers2019targetingtyro3axl pages 1-2): Kayla V. Myers, Sarah R. Amend, and Kenneth J. Pienta. Targeting tyro3, axl and mertk (tam receptors): implications for macrophages in the tumor microenvironment. Molecular Cancer, May 2019. URL: https://doi.org/10.1186/s12943-019-1022-2, doi:10.1186/s12943-019-1022-2. This article has 406 citations and is from a highest quality peer-reviewed journal.

30. (nguyen2014overexpressionofmertk pages 10-11): K. Nguyen, W. Tsou, D. Calarese, S. Kimani, Sukhwinder Singh, S. Hsieh, Yongzhang Liu, Bin Lu, Yi Wu, S. Garforth, S. Almo, S. Kotenko, and R. Birge. Overexpression of mertk receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity*. The Journal of Biological Chemistry, 289:25737-25749, Jul 2014. URL: https://doi.org/10.1074/jbc.m114.570838, doi:10.1074/jbc.m114.570838. This article has 106 citations.

31. (nguyen2014overexpressionofmertk pages 7-8): K. Nguyen, W. Tsou, D. Calarese, S. Kimani, Sukhwinder Singh, S. Hsieh, Yongzhang Liu, Bin Lu, Yi Wu, S. Garforth, S. Almo, S. Kotenko, and R. Birge. Overexpression of mertk receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity*. The Journal of Biological Chemistry, 289:25737-25749, Jul 2014. URL: https://doi.org/10.1074/jbc.m114.570838, doi:10.1074/jbc.m114.570838. This article has 106 citations.

32. (nguyen2014overexpressionofmertk pages 9-10): K. Nguyen, W. Tsou, D. Calarese, S. Kimani, Sukhwinder Singh, S. Hsieh, Yongzhang Liu, Bin Lu, Yi Wu, S. Garforth, S. Almo, S. Kotenko, and R. Birge. Overexpression of mertk receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity*. The Journal of Biological Chemistry, 289:25737-25749, Jul 2014. URL: https://doi.org/10.1074/jbc.m114.570838, doi:10.1074/jbc.m114.570838. This article has 106 citations.

33. (rothlin2014tyro3axland pages 1-2): Carla V. Rothlin, Jonathan A. Leighton, and Sourav Ghosh. Tyro3, axl, and mertk receptor signaling in inflammatory bowel disease and colitis-associated cancer. Inflammatory Bowel Diseases, 20:1472-1480, Aug 2014. URL: https://doi.org/10.1097/mib.0000000000000050, doi:10.1097/mib.0000000000000050. This article has 47 citations and is from a domain leading peer-reviewed journal.

34. (schoumacher2017keyrolesof pages 2-4): Marie Schoumacher and Mike Burbridge. Key roles of axl and mer receptor tyrosine kinases in resistance to multiple anticancer therapies. Current Oncology Reports, Mar 2017. URL: https://doi.org/10.1007/s11912-017-0579-4, doi:10.1007/s11912-017-0579-4. This article has 132 citations and is from a peer-reviewed journal.

35. (seitz2007macrophagesanddendritic pages 113-117): Heather M Seitz, Todd D Camenisch, Greg Lemke, H Shelton Earp, and Glenn K Matsushima. Macrophages and dendritic cells use different axl/mertk/tyro3 receptors in clearance of apoptotic cells. The Journal of Immunology, 178:5635-5642, May 2007. URL: https://doi.org/10.4049/jimmunol.178.9.5635, doi:10.4049/jimmunol.178.9.5635. This article has 457 citations.

36. (seitz2007macrophagesanddendritic pages 117-119): Heather M Seitz, Todd D Camenisch, Greg Lemke, H Shelton Earp, and Glenn K Matsushima. Macrophages and dendritic cells use different axl/mertk/tyro3 receptors in clearance of apoptotic cells. The Journal of Immunology, 178:5635-5642, May 2007. URL: https://doi.org/10.4049/jimmunol.178.9.5635, doi:10.4049/jimmunol.178.9.5635. This article has 457 citations.

37. (seitz2007macrophagesanddendritic pages 24-28): Heather M Seitz, Todd D Camenisch, Greg Lemke, H Shelton Earp, and Glenn K Matsushima. Macrophages and dendritic cells use different axl/mertk/tyro3 receptors in clearance of apoptotic cells. The Journal of Immunology, 178:5635-5642, May 2007. URL: https://doi.org/10.4049/jimmunol.178.9.5635, doi:10.4049/jimmunol.178.9.5635. This article has 457 citations.

38. (seitz2007macrophagesanddendritic pages 60-68): Heather M Seitz, Todd D Camenisch, Greg Lemke, H Shelton Earp, and Glenn K Matsushima. Macrophages and dendritic cells use different axl/mertk/tyro3 receptors in clearance of apoptotic cells. The Journal of Immunology, 178:5635-5642, May 2007. URL: https://doi.org/10.4049/jimmunol.178.9.5635, doi:10.4049/jimmunol.178.9.5635. This article has 457 citations.

39. (seitz2007macrophagesanddendritic pages 68-72): Heather M Seitz, Todd D Camenisch, Greg Lemke, H Shelton Earp, and Glenn K Matsushima. Macrophages and dendritic cells use different axl/mertk/tyro3 receptors in clearance of apoptotic cells. The Journal of Immunology, 178:5635-5642, May 2007. URL: https://doi.org/10.4049/jimmunol.178.9.5635, doi:10.4049/jimmunol.178.9.5635. This article has 457 citations.

40. (wang2013merreceptortyrosine pages 1-3): Y Wang, G Moncayo, P Morin, G Xue, M Grzmil, M M Lino, V Clément-Schatlo, S Frank, A Merlo, and B A Hemmings. Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme. Oncogene, 32:872-882, Apr 2013. URL: https://doi.org/10.1038/onc.2012.104, doi:10.1038/onc.2012.104. This article has 86 citations and is from a domain leading peer-reviewed journal.

41. (waterborg2018protectiveroleof pages 13-14): Claire E. J. Waterborg, Silke Beermann, Mathijs G. A. Broeren, Miranda B. Bennink, Marije I. Koenders, Peter L. E. M. van Lent, Wim B. van den Berg, Peter M. van der Kraan, and Fons A. J. van de Loo. Protective role of the mer tyrosine kinase via efferocytosis in rheumatoid arthritis models. Frontiers in Immunology, Apr 2018. URL: https://doi.org/10.3389/fimmu.2018.00742, doi:10.3389/fimmu.2018.00742. This article has 71 citations and is from a peer-reviewed journal.

42. (wu2005arolefor pages 1-2): Yi Wu, Sukhwinder Singh, M. Georgescu, and R. Birge. A role for mer tyrosine kinase in αvβ5 integrin-mediated phagocytosis of apoptotic cells. Journal of Cell Science, 118:539-553, Feb 2005. URL: https://doi.org/10.1242/jcs.01632, doi:10.1242/jcs.01632. This article has 319 citations and is from a domain leading peer-reviewed journal.

43. (wu2005arolefor pages 14-15): Yi Wu, Sukhwinder Singh, M. Georgescu, and R. Birge. A role for mer tyrosine kinase in αvβ5 integrin-mediated phagocytosis of apoptotic cells. Journal of Cell Science, 118:539-553, Feb 2005. URL: https://doi.org/10.1242/jcs.01632, doi:10.1242/jcs.01632. This article has 319 citations and is from a domain leading peer-reviewed journal.

44. (wu2005arolefor pages 7-9): Yi Wu, Sukhwinder Singh, M. Georgescu, and R. Birge. A role for mer tyrosine kinase in αvβ5 integrin-mediated phagocytosis of apoptotic cells. Journal of Cell Science, 118:539-553, Feb 2005. URL: https://doi.org/10.1242/jcs.01632, doi:10.1242/jcs.01632. This article has 319 citations and is from a domain leading peer-reviewed journal.

45. (wu2005arolefor pages 9-11): Yi Wu, Sukhwinder Singh, M. Georgescu, and R. Birge. A role for mer tyrosine kinase in αvβ5 integrin-mediated phagocytosis of apoptotic cells. Journal of Cell Science, 118:539-553, Feb 2005. URL: https://doi.org/10.1242/jcs.01632, doi:10.1242/jcs.01632. This article has 319 citations and is from a domain leading peer-reviewed journal.

46. (zhang2013discoveryofmer pages 1-2): Weihe Zhang, Andrew L. McIver, Michael A. Stashko, Deborah DeRyckere, Brian R. Branchford, Debra Hunter, Dmitri Kireev, Michael J. Miley, Jacqueline Norris-Drouin, Wendy M. Stewart, Minjung Lee, Susan Sather, Yingqiu Zhou, Jorge A. Di Paola, Mischa Machius, William P. Janzen, H. Shelton Earp, Douglas K. Graham, Stephen V. Frye, and Xiaodong Wang. Discovery of mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis. Journal of medicinal chemistry, 56 23:9693-700, Dec 2013. URL: https://doi.org/10.1021/jm4013888, doi:10.1021/jm4013888. This article has 69 citations and is from a highest quality peer-reviewed journal.

47. (zhang2013discoveryofmer pages 4-5): Weihe Zhang, Andrew L. McIver, Michael A. Stashko, Deborah DeRyckere, Brian R. Branchford, Debra Hunter, Dmitri Kireev, Michael J. Miley, Jacqueline Norris-Drouin, Wendy M. Stewart, Minjung Lee, Susan Sather, Yingqiu Zhou, Jorge A. Di Paola, Mischa Machius, William P. Janzen, H. Shelton Earp, Douglas K. Graham, Stephen V. Frye, and Xiaodong Wang. Discovery of mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis. Journal of medicinal chemistry, 56 23:9693-700, Dec 2013. URL: https://doi.org/10.1021/jm4013888, doi:10.1021/jm4013888. This article has 69 citations and is from a highest quality peer-reviewed journal.

48. (huang2009structuralinsightsinto pages 7-8): Xudong Huang, Patrick Finerty, John R. Walker, Christine Butler-Cole, Masoud Vedadi, Matthieu Schapira, Sirlester A. Parker, Benjamin E. Turk, Debra A. Thompson, and Sirano Dhe-Paganon. Structural insights into the inhibited states of the mer receptor tyrosine kinase. Journal of Structural Biology, 165:88-96, Feb 2009. URL: https://doi.org/10.1016/j.jsb.2008.10.003, doi:10.1016/j.jsb.2008.10.003. This article has 67 citations and is from a peer-reviewed journal.

49. (ma2011polymorphismsinthe pages 1-2): G. Z. Ma, J. Stankovich, T. Kilpatrick, M. Binder, and J. Field. Polymorphisms in the receptor tyrosine kinase mertk gene are associated with multiple sclerosis susceptibility. PLoS ONE, Feb 2011. URL: https://doi.org/10.1371/journal.pone.0016964, doi:10.1371/journal.pone.0016964. This article has 65 citations and is from a peer-reviewed journal.

50. (mcdaniel2018mertkmediatesintrinsic pages 9-13): Nellie K. McDaniel, Christopher T. Cummings, Mari Iida, Justus Hülse, Hannah E. Pearson, Eleana Vasileiadi, Rebecca E. Parker, Rachel A. Orbuch, Olivia J. Ondracek, Noah B. Welke, Grace H. Kang, Kurtis D. Davies, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp, Paul M. Harari, Randall J. Kimple, Deborah DeRyckere, Douglas K. Graham, and Deric L. Wheeler. Mertk mediates intrinsic and adaptive resistance to axl-targeting agents. Molecular Cancer Therapeutics, 17:2297-2308, Nov 2018. URL: https://doi.org/10.1158/1535-7163.mct-17-1239, doi:10.1158/1535-7163.mct-17-1239. This article has 54 citations and is from a peer-reviewed journal.

51. (nguyen2014overexpressionofmertk pages 1-2): K. Nguyen, W. Tsou, D. Calarese, S. Kimani, Sukhwinder Singh, S. Hsieh, Yongzhang Liu, Bin Lu, Yi Wu, S. Garforth, S. Almo, S. Kotenko, and R. Birge. Overexpression of mertk receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity*. The Journal of Biological Chemistry, 289:25737-25749, Jul 2014. URL: https://doi.org/10.1074/jbc.m114.570838, doi:10.1074/jbc.m114.570838. This article has 106 citations.

52. (nguyen2014overexpressionofmertk pages 3-4): K. Nguyen, W. Tsou, D. Calarese, S. Kimani, Sukhwinder Singh, S. Hsieh, Yongzhang Liu, Bin Lu, Yi Wu, S. Garforth, S. Almo, S. Kotenko, and R. Birge. Overexpression of mertk receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity*. The Journal of Biological Chemistry, 289:25737-25749, Jul 2014. URL: https://doi.org/10.1074/jbc.m114.570838, doi:10.1074/jbc.m114.570838. This article has 106 citations.